sorbin and SH3 domain containing 2Genealiases: ARGBP2 · PRO0618
Q-omics provides the consensus-scored SORBS2 profile across patient tissues and cancer cell-line models. SORBS2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SORBS2 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SORBS2 protein abundance shows 29,485 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, BLCA, and LUAD as cancer lineages where SORBS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SORBS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SORBS2 survival associations across molecular data types. SORBS2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SORBS2 RNA expression–survival associations across cancer types. High SORBS2 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, UVM, UCEC, KIRP and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SORBS2 RNA expression.
This table summarizes SORBS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SORBS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SORBS2 shows lower tumor expression in BLCA, THCA, KICH, HNSC, COAD and LUSC. The BLCA box plot shows higher SORBS2 RNA expression in normal versus tumor tissue (log2 FC = −4.287, t-test p < 0.001).
This table shows molecular features associated with SORBS2 in patient tissues and cancer cell lines. In patient samples, SORBS2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SORBS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
